A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients,…
Patricia Inácio, PhD
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inácio, PhD
RightEye’s Vision System, an advanced eye-tracking device that measures eye tremors to help diagnose Parkinson’s disease…
Sunovion Re-Submits Approval Request for APL-130277 to FDA for Treating Parkinson’s Off Periods
Sunovion Pharmaceuticals has re-submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), once…
Inflammation in the gut, a hallmark of autoimmune disorders such as inflammatory bowel disease, may contribute to an earlier…
Treatment with Aricept (donepezil) for six weeks does not seem to improve balance, either while standing or walking,…
Potential Therapy for Dopaminergic Neurons, CNM-Au8, Enter Phase 2 Trial in Parkinson’s Patients
CNM-Au8, an investigational therapy by Clene Nanomedicine, improved the survival of dopaminergic neurons, helped prevent loss of mitochondria,…
Kyowa Kirin’s Nourianz (istradefylline) tablets are now available in the United States as an add-on treatment for off…
Using its brain mapping platform, Inscopix will team up with researchers at the Broad Institute of MIT and…
Silverstein Foundation, Q-State Launch Company Aiming to Treat Parkinson’s Linked to GBA Mutations
The Silverstein Foundation for Parkinson’s with GBA together with Q-State Biosciences have launched Chamishi Therapeutics, a company aiming to…
In a recent review, scientists highlight the potential of gene editing technologies like CRISPR/Cas9 to not only understand the molecular…